Assessing Carl Zeiss Meditec (XTRA:AFX) Valuation After The ZEISS Crossbeam 750 FIB SEM Launch

ZEISS parent Carl Zeiss Meditec (XTRA:AFX) has drawn fresh attention after unveiling the ZEISS Crossbeam 750 FIB SEM, a high precision system aimed at semiconductor, nanofabrication, and materials science workflows.

See our latest analysis for Carl Zeiss Meditec.

While the ZEISS Crossbeam 750 launch has coincided with a 9.82% 1 month share price return and a 4.43% 7 day share price return, the 1 year total shareholder return of 50.70% and 5 year total shareholder return of 81.22% suggest that longer term momentum has been weak.

If this kind of specialist equipment story interests you, it could be a useful moment to scan the wider market for similar opportunities in robotics and automation via the 33 robotics and automation stocks

Yet with a value score of 5, an estimated 61% intrinsic discount and a 24% gap to the €32.17 analyst price target, you have to ask: is Carl Zeiss Meditec on sale, or is the market already pricing in future growth?

Most Popular Narrative: 19.4% Undervalued

With Carl Zeiss Meditec last closing at €25.94 against a narrative fair value of €32.17, the current price sits well below the modelled outcome using a 6.32% discount rate.

The recent approval of the VISUMAX 800 in China, earlier than expected, positions Carl Zeiss Meditec AG for potential revenue growth. The launch is expected to boost higher ASP (Average Selling Price) for both devices and treatment packs, enhancing future revenue streams.

Read the complete narrative.

Want to see what underpins that higher fair value? The narrative leans on gradually rising revenue, fatter profit margins and a future earnings multiple that looks very different to today.

Result: Fair Value of €32.17 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story can change quickly if organic sales stay weak and EBITA margins remain under pressure from pricing in China and an unfavourable product mix.

Find out about the key risks to this Carl Zeiss Meditec narrative.

Next Steps

The mix of cautious and optimistic signals here makes Carl Zeiss Meditec a nuanced story. Consider acting promptly, reviewing the data, and weighing up the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Carl Zeiss Meditec has caught your eye, do not stop here, the market is full of other opportunities that could suit your style and goals.

• Hunt for potential bargains by scanning companies that screen as 231 high quality undervalued stocks before prices and sentiment shift away from you.
• Build a sturdier income stream by focusing on businesses in the 480 dividend fortresses that already offer higher yields.
• Focus on resilience first by filtering for companies in the 300 resilient stocks with low risk scores that combine steadier risk scores with more robust profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com